| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
TLR3[2], RIG-I[2], MDA5[2], apoptosis[2]
Poly (I:C):Kanamycin (1:1) (sodium) targets two different biological entities. The poly(I:C) component targets Toll-like receptor 3 (TLR3) and the retinoic acid-inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). The kanamycin component targets the bacterial 70S ribosomal subunit, binding to it and causing miscoding and inhibition of translocation. |
|---|---|
| ln Vitro |
Poly(I:C) sodium (20 ng/mL; 24 hours; WM793, WM278, WM239A, WM9, and 1205Lu cells) treatment dramatically decreased cell viability over the course of the treatment, going from 100% of control to 20%. 50% of the total[1]. Treatment of 1205Lu cells with 200 ng/mL of poly(I:C) sodium for 24 hours causes apoptosis in these cells[1]. Melanoma cells treated with polyinosinic-polycytidylic acid (3 ng/mL; 24 hours; 1205Lu cells) express IFN-β. The activation of IFN-β by Poly(I:C) sodium needs IPS-1 as well as RIG-I and MDA-5, respectively, as demonstrated by the silencing of these two proteins [1]. In melanoma cells, treatment with Poly(I:C) sodium (5 ng/mL) for 24 hours revealed the presence of caspase-9 and caspase-8 active subunits [1]. Good antibacterial action against a range of mycobacterial strains is demonstrated in vitro by kanamycin (0.1-100 μg/mL; 2 weeks) (MIC=1-5 μg/mL) [3].
In vitro, poly(I:C) is a synthetic analog of double-stranded RNA and an agonist of TLR3, RIG-I, and MDA5. This activity induces the production of type I interferons and pro-inflammatory cytokines. Kanamycin is an orally active antibacterial agent that inhibits translocation and causes miscoding by binding to the 70S ribosomal subunit, showing good activity against M. tuberculosis and K. pneumoniae. |
| ln Vivo |
In NOD/SCID immunodeficient mice injected with 1205Lu cells, poly (I:C) sodium suppresses the formation of tumors. Human DNA levels were 50% lower in mice given Poly (I:C) sodium treatment[1]. Mycobacterium bovis development in the lungs and spleens of mice is inhibited by kanamycin (2, 4 mg/kg; subcutaneous injection; once daily, six times weekly for 3 weeks) [3]. The growth of Klebsiella pneumoniae DT-S in the lungs, trachea, and blood of mice is inhibited in a dose-proportional manner by kanamycin (1.25, 5 mg/kg; subcutaneous injection; single injection 3 hours after infection). Furthermore, it raises the survival rate of mice [4].
In vivo, poly(I:C) sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses. It can also be used as an immunotherapeutic agent to induce apoptosis in cancer cells. Kanamycin is used to treat bacterial infections, particularly tuberculosis and pneumonia. The combination is used to study immune modulation and antimicrobial therapy. |
| Enzyme Assay |
A cell-free TLR3 binding assay is typically performed using a TR-FRET assay or SPR with purified TLR3 protein. The poly(I:C) component of the complex binds to TLR3, triggering a signaling cascade. For kanamycin, a cell-free binding assay would measure its binding to the bacterial 70S ribosomal subunit or purified ribosomal RNA using SPR or a filter-binding assay.
|
| Cell Assay |
HEK293 cells stably expressing human TLR3 are seeded in 96-well plates. Cells are treated with Poly (I:C):Kanamycin (1:1) (sodium) (0.1-100 ug/mL) for 6-24 hours. Supernatants are collected, and IFN-beta, IL-6, and TNF-alpha levels are measured by ELISA. For antiviral assays, cells are infected with a virus (e.g., VSV) after poly(I:C) treatment, and viral titers are determined by plaque assay.
|
| Animal Protocol |
Poly (I:C):Kanamycin (1:1) (sodium) can be used as an immunotherapeutic agent in a mouse tumor model. Female C57BL/6 mice are implanted subcutaneously with melanoma cells (e.g., B16-F10). When tumors reach 50-100 mm3, mice are injected intratumorally with the complex (5-10 ug). Tumor growth is monitored. Immune cell infiltration (CD8+ T cells) is analyzed by flow cytometry.
|
| ADME/Pharmacokinetics |
Poly(I:C) as a component of the complex is known to have a short plasma half-life (minutes) due to rapid degradation by serum nucleases. Kanamycin is poorly absorbed orally and has a half-life of 2-3 hours in humans. The complex is designed for local or injectable administration. The sodium salt form enhances stability and solubility. Specific PK data for the 1:1 complex are not available.
|
| Toxicity/Toxicokinetics |
Poly(I:C) can induce inflammatory responses and cytokine storm at high doses, which can be toxic. Kanamycin is associated with nephrotoxicity and ototoxicity with high or prolonged doses. The complex is expected to have a similar safety profile to its components. It should be used with caution. Standard safety precautions for handling RNA and antibiotics should be followed.
|
| References |
|
| Additional Infomation |
Poly (I:C):Kanamycin (1:1) (sodium) is a research-grade complex and is not an approved drug. It is an equal-proportion complex of Poly (I:C) and Kanamycin. Poly(I:C) is a synthetic dsRNA analog and a TLR3 and RIG-I/MDA5 agonist, while Kanamycin is an antibacterial agent. This research tool is used to study immune responses, antimicrobial resistance, and antiviral therapies.
|
| Related CAS # |
Polyinosinic-polycytidylic acid sodium;42424-50-0
|
|---|---|
| Appearance |
Solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~50 mg/mL DMSO :< 1 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
